Related Experiment Video
Updated: Apr 3, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study
Elise A Mitri1,2,3, Luke R Fletcher4,5,6, Sara Vogrin1,2
1Department of Infectious Diseases and Immunology, Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, Victoria, Australia.
Insights
Inpatient penicillin direct oral challenge (DOC) is safe and effective for penicillin allergy assessment. This method improved penicillin prescribing and reduced the use of restricted antibiotics in hospitalized patients.
Area of Science:
- Infectious Diseases
- Clinical Pharmacology
- Health Services Research
Background:
- Penicillin allergy is reported by ~10% of hospitalized patients globally, leading to suboptimal antibiotic use and poorer outcomes.
- Limited evidence exists on the effectiveness and implementation of inpatient penicillin direct oral challenge (DOC).
Purpose of the Study:
- To evaluate the effectiveness and implementation of an inpatient penicillin DOC strategy.
- To assess the impact of DOC on antibiotic prescribing patterns.
Main Methods:
- A prospective, multicenter, international hybrid effectiveness-implementation study involving 40 hospitals.
- Adult inpatients with penicillin allergy were assessed using the National Antibiotic Allergy Network (NAAN) App and underwent DOC or assessment only.
- Audit and feedback were provided to sites, and observational data emulated a target trial.
Main Results:
- Of 5121 assessed, 1573 underwent DOC, with 95.5% successfully delabeled.
- DOC participants were more likely to receive penicillin (RR 13.25) and less likely to receive WHO "Watch" or "Reserve" antibiotics (RR 0.73).
- 77 clinicians adopted the NAAN App within 6 months.
Conclusions:
- Multidisciplinary adoption of inpatient penicillin DOC is safe and feasible.
- Penicillin DOC significantly improved penicillin prescribing and reduced the use of restricted antibiotics.
Background:
Approximately 10% of hospitalized patients globally report a penicillin allergy, leading to inappropriate antibiotic prescribing and inferior healthcare outcomes. Evidence supporting the effectiveness and widespread implementation of inpatient penicillin direct oral challenge (DOC) is limited.
Methods:
A prospective, multicenter, international type 2 hybrid effectiveness-implementation study was conducted in 40 hospitals across 8 countries between November 2022 and May 2025. Adult inpatients with a penicillin allergy underwent assessment using a digital penicillin allergy toolkit (National Antibiotic Allergy Network [NAAN] App). According to site clinical practice, participants received penicillin DOC (effectiveness intervention) or assessment only. Participating sites received bimonthly audit and feedback at least 3 months after site activation (implementation strategy). Observational data were used to emulate a target trial to examine secondary effectiveness outcomes, including antibiotic prescribing at 90 days in DOC versus non-DOC participants. The primary implementation outcome was adoption of the NAAN App within 6 months of site activation.
Results:
Among 5121 participants assessed, 1573 (30.7%) underwent DOC, of which 1502 (95.5%) were delabeled. Of 71 (4.5%) participants with a positive DOC, 6 (0.4%) had a serious adverse event. Of 1852 inpatients in the target trial analysis, 892 underwent DOC and 960 underwent assessment only. Participants who underwent DOC were more likely to be prescribed penicillin (risk ratio [RR], 13.25 [95% confidence interval {CI}, 7.82-22.46]), and less likely to be prescribed World Health Organization (WHO) "Watch" or "Reserve" antibiotics (RR, 0.73 [95% CI, .60-.89]) at 90 days post evaluation. Within 6 months of site activation, 77 clinicians adopted the NAAN App.
Conclusions:
Multidisciplinary adoption of inpatient penicillin DOC was safe and significantly improved penicillin prescribing and reduced use of WHO restricted antibiotics.
Related Concept Videos
Allergic Reactions: Anaphylaxis
Allergic Reactions
Allergic Drug Reactions
Production of Antibiotics
Drug Toxicity: Allergic Reactions

